Investor Presentaiton

2022 pipeline progress and momentum World leader in infectious disease based on science of the immune system Pipeline vaccines and medicines 69 New approvals since 2017 >20 • 2022 pipeline highlights Apretude: launched first and only long- acting injectable for HIV prevention • Cabenuva: regulatory approval for every- two-month dosing (US) ⚫ RSV¹ older adults vaccine: regulatory submission (US, EU, JP) Gepotidacin: phase III stopped early for efficacy in patients with uncomplicated UTI² Bepirovirsen: phase IIb presented at AASLD³ and published in the New England Journal of Medicine Business Development Acquisition of Affinivax • Access to disruptive MAPS4 technology Phase II 24-valent pneumococcal and 30+ valent pre-clinical vaccine candidates Acquisition of Sierra Oncology • Momelotinib for myelofibrosis patients with anaemia; regulatory submission (US, EU) Exclusive licence with Spero Therapeutics LLC Access to tebipenem HBr5, a late-stage antibiotic for complicated UTI² 1. Respiratory syncytial virus 2. Urinary tract infection 3. The American Association for the Study of Liver Diseases 4. Multiple Antigen Presenting System 5. Tebipenem pivoxil hydrobromide GSK 8

View entire presentation